AVAX Technologies, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AVXT research report →
Companywww.avax-tech.com
AVAX Technologies, Inc. , a development stage biopharmaceutical company, develops autologous cell vaccine technologies for the treatment of cancer. The company's product candidates that have completed phase II clinical trials include M-VAX for the treatment of melanoma and O-VAX for the treatment for ovarian cancer.
- CEO
- Adele Sommerfeld
- IPO
- 1997
- Employees
- 9
- HQ
- Philadelphia, PA, US
Price Chart
Valuation
- Market Cap
- $6.89K
- P/E
- -0.00
- P/S
- 0.01
- P/B
- 0.00
- EV/EBITDA
- 0.96
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- 1084.07%
- Net Margin
- -1038.84%
- ROE
- -344.15%
- ROIC
- -215.04%
Growth & Income
- Revenue
- $617.38K · -15.98%
- Net Income
- $-6,413,648 · -19.76%
- EPS
- $-0.05 · 38.19%
- Op Income
- $6.69M
- FCF YoY
- -17.54%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -55.48
- Avg Volume
- 109
Get TickerSpark's AI analysis on AVXT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 1, 04 | SPANA CARL | other | 40,000 |
Our AVXT Coverage
We haven't published any research on AVXT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AVXT Report →